Cargando…

2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa

BACKGROUND: By targeting penicillin binding protein-3, the AmpC β-lactamase, and MurA, another enzyme involved in cell wall synthesis, with the ceftazidime–avibactam–fosfomycin combination, we previously overcame multidrug resistance (MDR) in vitro in an archived collection of Pseudomonas aeruginosa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp-Wallace, Krisztina M, Zeiser, Elise T, Becka, Scott A, Park, Steven T, Winkler, Marisa L, Nguyen, Kevin, Singh, Indresh, Sutton, Granger, Fouts, Derrick E, Ellis-Grosse, Evelyn J, Drusano, George L, Perlin, David S, Bonomo, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253269/ http://dx.doi.org/10.1093/ofid/ofy210.2038

Ejemplares similares

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023)

Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans
por: Becka, Scott A., et al.
Publicado: (2018)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
por: Barnes, Melissa D., et al.
Publicado: (2017)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
por: Oliva, Alessandra, et al.
Publicado: (2021)

The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States
por: Becka, Scott A., et al.
Publicado: (2022)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

2160. Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy
por: Brunetti, Florencia, et al.
Publicado: (2023)

OMeta: an ontology-based, data-driven metadata tracking system
por: Singh, Indresh, et al.
Publicado: (2019)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020)

Structural Analysis of The OXA-48 Carbapenemase Bound to A “Poor” Carbapenem Substrate, Doripenem
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2019)

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
por: Das, Shampa, et al.
Publicado: (2019)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
por: Mancuso, Alessandro, et al.
Publicado: (2023)

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
por: Soriano, Alex, et al.
Publicado: (2023)

1385. Efficacy of Ceftazidime–Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-Lactamase Producing-Enterobacteriaceae (MBL)
por: Lodise, Thomas P, et al.
Publicado: (2018)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2020)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
por: Montero, María M., et al.
Publicado: (2021)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
por: Borde, Kalyani, et al.
Publicado: (2023)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations
por: Keepers, Tiffany R., et al.
Publicado: (2015)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases
por: Frère, Jean-Marie, et al.
Publicado: (2020)

Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019)

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019)

Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
por: DUMLU, Rıdvan, et al.
Publicado: (2022)

2582. Real-World Analysis of the Outcomes of Patients Treated with Ceftazidime-Avibactam
por: Wazzi-Mkahal, Rayyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6be296mls33manbd2sd7mu57c6